Nautilus Biotechnology, INC. (NAUT) — 10-Q Filings

10-Q Filings (6)

• Nautilus Biotech Narrows Q3 Loss Amidst Reduced R&D Spend — Oct 28, 2025 Risk: high
  Nautilus Biotechnology, Inc. (NAUT) reported a net loss of $13.574 million for the three months ended September 30, 2025, an improvement from a net loss of $16.
• Nautilus Biotech Posts Zero Revenue, Widens Q2 Loss to $28.5M — Jul 31, 2025 Risk: high
  Nautilus Biotechnology, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods, as the company remain
• Nautilus Biotechnology Files Q1 2025 10-Q — Apr 29, 2025 Risk: medium
  Nautilus Biotechnology, Inc. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as ARYA Sciences Acquisition Corp III,
• Nautilus Biotechnology Files Q3 2024 10-Q — Oct 29, 2024 Risk: medium
  Nautilus Biotechnology, Inc. filed its quarterly report for the period ending September 30, 2024. The company, formerly known as ARYA Sciences Acquisition Corp
• Nautilus Biotechnology Files Q2 2024 10-Q — Jul 30, 2024 Risk: medium
  Nautilus Biotechnology, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business
• Nautilus Biotechnology, Inc. Files 10-Q for Period Ending March 31, 2024 — Apr 30, 2024 Risk: low
  Nautilus Biotechnology, Inc. (NAUT) filed a Quarterly Report (10-Q) with the SEC on April 30, 2024. Nautilus Biotechnology, Inc. filed a 10-Q report for the per

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX